Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
7.0800
+0.1700 (2.46%)
NASDAQ · Last Trade: Apr 26th, 5:16 AM EDT
Detailed Quote
Previous Close
6.910
Open
6.770
Bid
6.370
Ask
7.140
Day's Range
6.770 - 7.241
52 Week Range
2.700 - 18.00
Volume
49,879
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
871,447
Chart
About Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
Quantum Biopharma Ltd. is a biotechnology company focused on developing innovative therapies and treatments for a range of diseases, leveraging advanced biopharmaceutical technologies. The company specializes in creating novel drugs and biologics aimed at improving patient outcomes and addressing unmet medical needs in various therapeutic areas. Through a combination of cutting-edge research and strategic partnerships, Quantum Biopharma is actively engaged in bringing its proprietary products from the lab to clinical trials, with the ultimate goal of enhancing healthcare options and improving the quality of life for patients worldwide. Read More
Quantum BioPharma (NASDAQ: QNTM) has appointed Kevin Malone as an advisor to its Board of Directors. A seasoned financial advisor with over 40 years of family experience in wealth management, Malone is known for his work in market pattern recognition and his outspoken stance against trading manipulation. As founder of Malone Wealth, he champions financial literacy and advocates against naked short selling, a mission closely aligned with Quantum’s shareholder protection values and therapeutic focus.
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announced it will host a Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern time to discuss its recent year-end financial results, regulatory initiatives, commercial-readiness activities and anticipated milestones.
Quantum BioPharma (NASDAQ: QNTM) has appointed Kevin Malone as an advisor to its Board of Directors. A seasoned financial advisor with over 40 years of family experience in wealth management, Malone is known for his work in market pattern recognition and his outspoken stance against trading manipulation. As founder of Malone Wealth, he champions financial literacy and advocates against naked short selling, a mission closely aligned with Quantum’s shareholder protection values and therapeutic focus.
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. The company recently announced corporate updates, including the grant of 60,000 restricted share units (each, an “RSU”) pursuant to its equity incentive plan, which are subject to certain vesting criteria. In addition, Quantum BioPharma announced that its board of directors authorized and approved the settlement of outstanding debt owed to arm’s length parties by issuing Class B Shares, each at a deemed price of US$6.75.
In this video lesson, I look at the overall market, what I expect the market to do in the intermediate term, my game plan per all my time frames and accounts.
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative, metabolic and alcohol misuse disorders, announced that a reconsideration motion filed by former CEO Dr. Raza Bokhari was fully dismissed by the Court of Appeal for Ontario. Bokhari, terminated for cause in 2021, had previously lost an arbitration claiming wrongful dismissal, which resulted in a total cost award of approximately C$2.81 million plus interest. Additional court-awarded costs have raised the amount due to over C$3 million. Quantum BioPharma has initiated U.S. collection proceedings, resulting in a judgment entered in its favor by the U.S. District Court for the Eastern District of Pennsylvania. Bokhari’s appeal is ongoing with a stay in place, backed by a supersedeas bond of more than $2.8 million.
Quantum BioPharma (NASDAQ: QNTM) has announced that its licensee, Celly Nutrition Corporation, secured a strategic partnership with the Asian American Trade Associations Council (“AATAC”) to accelerate retail expansion of unbuzzd, a beverage aimed at reducing blood alcohol levels and restoring mental clarity. The collaboration will focus on promoting unbuzzd ’s “On-the-Go Powder Stick Packs” through AATAC’s vast network, which spans over 80,000 retail locations, including major chains like 7-Eleven, Shell and Chevron. The agreement is expected to significantly boost sales and consumer reach in the health and wellness space.
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nutrition Corporation (“Celly Nutrition”), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – has secured a landmark partnership with the Asian American Trade Associations Council (“AATAC”) to expand the retail availability of unbuzzd™, increase sales, and recruit new customers. This partnership will focus on unbuzzd™’s convenient “On-the-Go Powder Stick Packs” which have been scientifically proven to accelerate the reduction of blood alcohol levels and restore mental alertness.
Quantum BioPharma (NASDAQ: QNTM) has announced that its licensee, Celly Nutrition Corporation, is launching the alcohol-mitigating beverage unbuzzd in Puerto Rico through FUSION Distribution Group. The science-backed product, which speeds up alcohol metabolism and eases hangover symptoms, will be sold in “On-the-Go Powder Stick Packs” and distributed across major retailers including Walmart, Walgreens, and Costco. FUSION’s network spans Puerto Rico, the Caribbean, and parts of Central and South America.
Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region
Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company advancing innovative biotech assets, announced a joint clinical study with Massachusetts General Hospital to evaluate a novel PET imaging technique for tracking myelin integrity in multiple sclerosis (MS) patients. The study will assess [18F]3F4AP PET scans as a biomarker for demyelination, complementing MRI scans in both progressive and relapsing-remitting MS. The technique may enhance diagnostics in trials involving remyelinating and neuroprotective drugs, including Quantum’s Lucid-MS, which has shown promise in preserving the myelin sheath in preclinical models.
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that on March 31, 2025 it has entered into a joint clinical study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique to monitor myelin integrity and demyelination in people with multiple sclerosis (MS).
Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company, announced the closing of its final tranche in a debenture unit offering, raising a total of CAD $5 million. Proceeds will support research and development, commercialization efforts, and working capital, with management stating the funding provides runway through the first quarter of 2027. The company also began developing a hospital-use formulation of rekvry, its alcohol misuse treatment designed to alleviate healthcare system strain.
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final tranche (“Final Tranche”) of the offering announced on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for $2,420,000 as part of this Final Tranche bringing the total amount raised to $5 million. The Company will use the proceeds to advance the research and development of its innovative drug candidates, advancing commercialization and monetization of certain assets, and for general working capital purposes. Management now believes there is enough cash to execute on these advances until at least the first quarter of 2027.
Quantum BioPharma (NASDAQ: QNTM) reported its financial results for the fourth quarter and year ended Dec. 31, 2024, highlighting a strengthened balance sheet and strategic advances across its clinical programs. The company removed its Material Uncertainty Related to Going Concern, with $12.1 million in cash and a 36% reduction in net cash used for operations year over year. Operating expenses dropped over 32% to $16.1 million, while net loss narrowed 18% to $14.9 million. Quantum completed a clinical trial for its unbuzzd alcohol detox supplement, which showed a 40% faster reduction in blood alcohol concentration among participants. unbuzzd is now expanding through a master distribution agreement across Latin America and ongoing U.S. sales. The company also completed a Phase 1 trial of its multiple sclerosis treatment Lucid-MS, which was deemed safe and well-tolerated, with Phase 2 preparations underway. Other initiatives included a dual listing on Upstream, crypto treasury diversification, and the early development of rekvry, an alcohol misuse treatment for emergency settings.
Quantum BioPharma (NASDAQ: QNTM) has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will remain as an advisor. Lynch, a prominent advocate against micro-cap stock manipulation and CEO of Power Nickel (TSXV: PNPN), brings deep experience in biotech, mining finance and market reform. He is also a co-founder of Cardiol Therapeutics (NASDAQ: CRDL) and a consultant to bionxt solutions. As part of the appointment, Quantum granted Lynch 50,000 stock options at C$9.90 per share, expiring March 26, 2027.
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company.
Celly Nutrition has to pay 7% royalty on sales of alcohol detox product unbuzzd to Quantum until payments total $250 million and 3% royalty afterwards.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition Corporation has introduced a new format of its unbuzzd beverage supplement—“On-the-Go Powder Stick Packs”—now sold in 8-pack display boxes. Designed for convenience and portability, the new packaging supports broader retail distribution in convenience, liquor, and drug stores across the United States. The product, which accelerates alcohol metabolism and reduces hangover symptoms, is also available online in 3-pack, 8-pack, and 18-pack formats. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives up to 7% in royalties on sales of unbuzzd . The company also renewed a 45-day market awareness campaign with Life Water Media beginning March 26.
TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,500,000 worth of Bitcoin (BTC) and other cryptocurrencies, growing and increasing its crypto assets as part of its strategic efforts. This brings the total amount of Bitcoin (BTC), and other cryptocurrencies purchased to USD $3,500,000. As previously announced, the company will continue to allow for future financings and other transactions to be carried out in cryptocurrency.
